News | March 06, 2024
Bayer strengthens pharma portfolio with new cardiology drug acoramidis
Acquisition of exclusive commercialization rights for European markets
Acquisition of exclusive commercialization rights for European markets
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Medway setup a state-of-the-art Heart Institute in Chennai
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
This acquisition marks Max Healthcare's entry into Lucknow
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Subscribe To Our Newsletter & Stay Updated
